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Unequal Efficacy of Pyridinium Oximes in Acute
Organophosphate Poisoning
Biljana Antonijevic and Milos P. Stojiljkovic
The use of organophosphorus pesticides results in toxicity risk to non-target organisms.
Organophosphorus compounds share a common mode of action, exerting their toxic effects
primarily via acetylcholinesterase (AChE) inhibition. Consequently, acetylcholine accumulates in the
synaptic clefts of muscles and nerves, leading to overstimulation of cholinergic receptors. Acute
cholinergic crisis immediately follows exposure to organophosphate and includes signs and
symptoms resulting from hyperstimulation of central and peripheral muscarinic and nicotinic
receptors. The current view of the treatment of organophosphate poisoning includes three
strategies, i.e. the use of an anticholinergic drug (e.g., atropine), cholinesterase-reactivating agents
(e.g.,oximes) and anticonvulsant drugs (e.g., benzodiazepines).Oximes, as a part of antidotal therapy,
ensure the recovery of phosphylated enzymes via a process denoted as reactivation of inhibited
AChE. However, both experimental results and clinical findings have demonstrated that different
oximes are not equally effective against poisonings caused by structurally different
organophosphorus compounds.Therefore, antidotal characteristics of conventionally used oximes
can be evaluated regarding how close the certain substance is to the theoretical concept of the
universal oxime. Pralidoxime (PAM-2), trimedoxime (TMB-4), obidoxime (LüH-6), HI-6 and HLö-7
have all been demonstrated to be very effective in experimental poisonings with sarin and VX.TMB-4 and
LüH-6 may reactivate tabun-inhibited AChE, whereas HI-6 possesses the ability to reactivate the
soman-inhibited enzyme. An oxime HLö-7 seems to be an efficient reactivator of AChE inhibited
by any of the four organophosphorus warfare agents. According to the available literature, the
oximes LüH-6 and TMB-4, although relatively toxic, are the most potent to induce reactivation of
AChE inhibited by the majority of organophosphorus pesticides. Since there are no reports of
controlled clinical trials on the use of TMB-4 in human organophosphate pesticide poisoning, LüH-6
may be a better option.
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Highly toxic organophosphorus compounds (OPCs) are
widely used for pest control and for the control of vector-borne
diseases. These compounds also include the nerve poisons
that are among the most toxic group of chemical warfare
agents. Toxicology of organophosphates, as well as the
therapeutic approaches in acute organophosphate poisoning,
is of importance to many different groups of health
professionals. The management of OPC poisoning is
complex and includes nonspecific and specific measures.
The dominant underlying toxicodynamic mechanism in
organophosphate poisoning is inhibition of acetylcholinesterase
(AChE). Oximes, as cholinesterase reactivators, are the only
causal antidotes used against OPCs. Unfortunately, there are
no known oximes that are efficient reactivators of
cholinesterase inhibited by any of the known OPCs.
Moreover, controlled clinical studies proving the efficacy of
oximes in humans are mostly lacking.
Historical Overview
The first synthesis of an OPC was performed in the middle
of the 19th century by Moschnine in Professor Wurtz’s
laboratory in Paris. The first OPC ever synthesized was
tetraethylpyrophosphate and the process was first published
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in 1854 by de Clermont. However, von Hofmann was the first
scientist to synthesize an OPC with direct phosphorus-carbon
linkage (methylphosphoryl dichloride) in 1873. In the 
next century, Lange and von Krueger synthesized
dialkylphosphonofluoridates, obtaining many OPCs with
insecticidal or fungicidal properties. Between 1934 and 1944
Schrader’s team synthesized approximately 2000 OPCs and in
1944 two well-known organophosphorus insecticides, 
diethyl-p-nitrophenylphosphate (paraoxon, E600) and 
diethyl-p-nitrophenylthiophosphate (parathion, E605), were
synthesized. As early as 1935, the Nazi Germany government
insisted on redefining Schrader’s primal aim from
organophosphorus insecticides to organophosphorus
chemical warfare agents (e.g., tabun, sarin, soman). In a
series of fluorine-containing esters, besides sarin and soman,
Schrader also developed diisopropyl phosphorofluoridate
(DFP). Also during this same period, British and American
scientists were evaluating the toxic properties of DFP and
other alkyl phosphorofluoridates. Although initially designed
as a potential chemical warfare agent, DFP became a model
substance widely used throughout the pharmacological
community for studying cholinergic neurotransmission. The
fourth chemical warfare agent, VX, was synthesized a decade
later in 1957 by Tammelin.1
During the same period, Russian scientists developed the 
so-called Russian VX (VR). Another structural analog of VX,
known as Chinese VX (CVX), was also developed. Kuca and 
co-workers2 showed that the VX agent was half-fold more
toxic in comparison with VR with in vitro experiments using
rat, pig and human brain homogenate. However, examination
of reactivity towards human and pig AChE demonstrated the
following rank order of inhibitory potency: VR>CVX>VX.3
Structural formulae of some organophosphorus chemical
warfare agents are given in figure 1.
In the late 1980s and early 1990s, chemists in Russia
produced several new agents, including Novichok-5 and
Novichok-7. According to the Russian scientist-defector
Mirzayanov, Novichoks are binary nerve agents, i.e., agents
that become lethal only after mixing of the two otherwise
benign components, and their toxicity is allegedly 10 to 100
times greater than one of the conventional nerve agents.
Unlike VX, Novichok’s reactivability with oximes seems to
be at least as difficult as in soman poisoning. The
intermediate volatility agent also belongs to the group of
organophosphate nerve agents.4 To our knowledge, there are
no peer reviewed, scientific articles concerning chemical and
toxicological properties of Novichoks and intermediate
volatility agents, although there are some press reports on them.
After World War II, OPCs were reintroduced worldwide for
pesticide use, as originally intended. In the decades since,
numerous structurally different OPCs have been synthesized.
Currently more than 100 different OPCs are used mainly as
insecticides in agriculture and gardening.5-7
Toxicological Relevance
In industrialized countries, severe intoxication of OPCs
generally results from oral intake, whereas inhalation or
dermal absorption does not play a major role. In developing
countries, the most common cause of pesticide poisonings is
due to occupational exposure. However, a review of poisoning
studies in developing countries reveals that pesticide
poisonings associated with high mortality rates are usually
the result of self-poisoning. Particularly, a great number of
victims was present in rural regions due to the widespread
availability of acutely toxic pesticides used in agriculture.8,9
Organophosphorus pesticides cause several hundreds of
thousands of victims per year worldwide.6 While some of
these intoxications may be attributed to accidental exposure,
Figure 1. Structural formulas for organophosphorus chemical warfare agents.
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the majority of casualties result from suicidal attempts with
ingestion of multiple lethal doses. Therefore, the
indiscriminate use of these pesticides results in a toxicity risk
to non-target organisms and environmental pollution.
Due to their high toxicity, OPCs bear a potential risk for use in
war conflicts and terrorist attacks. Namely, the repeated use of
nerve agents during the Iran–Iraq war in the 1980s,10 against
civilians by Iraqi troops,11 and during terrorist attacks by the
Aum Shinrikyo sect in Japan12-15 emphasize the constant
threat and need for increased awareness of the potential for
future homicidal attempts, as well as the urgent need for the
development of an effective medical treatment regimen.16,17
The mechanism of action of OPCs, as well as factors contributing
to toxic response, will be briefly discussed in this paper.
Treatment of acute poisoning caused by this class of substances
will be considered through a correlation of experimental data and
clinical findings, with special attention to oxime efficacy against
chemically different cholinesterase inhibitors.
Mechanism of Action of OPCs
The basic chemical structure of all OPCs is described 
by Schrader’s formula (figure 2).18 The structural diversity 
of OPCs is due to different substituents at the phosphorus
atom. Substituents at R1 and R2 are alkyl, alkoxy, alkylthio or
amino groups, and substituent at X is a labile acyl 
residue (halide, cyano, phenol or thio group), known as the 
leaving group.
The reactivity of OPCs varies upon chemical structure.
Electrophilicity of the phosphorus atom is crucial for the
biological actions of OPCs. Organophosphates that have
double bonds between phosphorus and oxygen atoms are
highly electrophilic at the phosphorus atom and accordingly
are highly reactive. Groups that enhance the reactivity of the
phosphorus atom are nitro, cyano, halogen, ketone and
carboxylic ester. Deactivating groups include hydroxyl and
carboxylic acid. Organophosphates share a common mode of
action,19 exerting their toxic effects primarily via AChE (EC
3.1.1.7) inhibition.20-22 Cholinesterases are hydrolytic
enzymes whose existence was first proposed by Sir Henry
Hallet Dale in 1914.23 During his research on cholinergic
mechanisms, he proposed that “in the blood at body
temperature an esterase contributed to the removal of the
active ester from the circulation.” The butyrylcholinesterase
(BuChE, EC 3.1.1.8) and AChE are both blocked by OPCs.
Although both cholinesterases hydrolyze acetylcholine (ACh)
and other choline esters, they differ in their relative affinity
for some substrates. AChE is an enzyme of vital importance,
as well as one of the most efficient enzymes known. A 
single enzyme molecule is capable of hydrolyzing 
6 x 105 molecules of ACh per minute. Muscle and nerve
AChE are only present in the synaptic cleft and cannot be
measured directly. Since erythrocyte AChE has a similar
structure as the synaptic enzyme, it appears to be a suitable
parameter to reflect various reactions at the synaptic site.24,25
Therefore, its measurement is of high value for therapeutic
management, especially oxime administration, during the
course of intoxication.17
Inhibition of BuChE, whose physiological role is still unclear,
can be ascertained by clinical laboratory procedures and will
confirm the clinical diagnosis. Even more, BuChE has been
recognized as a bioscavenger of OPCs, thereby decreasing the
organophosphate concentration in the organism.26 Namely,
among the enzymes examined as potential scavengers of
OPCs, significant advances have been made by using AChE
and BuChE.27-29 Human serum BuChE is proposed as an
exogenously administered prophylactic for human use30 due
to the following facts: it reacts rapidly with all highly toxic
OPCs, offering a broad range of protection for nerve agents
including soman, sarin, tabun and VX; it possesses a very
long retention time in human circulation and is readily
absorbed from sites of injection; the enzyme is from a human
source and should not produce any adverse immunological
responses upon repeated administration to humans.31
However, the production of native human BuChE requires
large amounts of plasma leading to the development of
technologies to produce recombinant human BuChE.32
Despite the fact that both AChE and BuChE serve as
diagnostic tools, after the exposure resulting in inhibition
levels <20% with no clinical signs and symptoms of
organophosphate poisoning, it is necessary to bear in mind
the uncertainty due to marked inter-individual variations of
AChE and BuChE activities and to intra-individual variation
of BuChE activities.16,33 Another factor complicating the
interpretation of erythrocyte AChE activity is that inhibition
of this enzyme probably overestimates the inhibition of AChE
in the nervous system.33 Namely, in the case of an irreversible
inhibition, recovery of erythrocyte AChE depends on de novo
production and release from the bone marrow of new
erythrocytes with uninhibited AChE. The recovery rate of
erythrocyte AChE has been estimated to be 1%, whereas the
half-life of AChE resynthesis in the nervous system has been
reported to be 5 to 7 days. Therefore, AChE in brain will
recover earlier than in red blood cells.
Molecular Mechanisms of Organophosphate Toxicity
OPCs and their active metabolites are electrophilic molecules
with moderate to high potency for phosphylation (denotes
both phosphorylation and phosphonylation) of the serine
hydroxyl group located at the active site of AChE. This
phosphylation occurs by the loss of the leaving group and the
establishment of a covalent bond with AChE through the
serine hydroxyl. The resultant phosphylated AChE is typically
Figure 2. Schrader’s formula for organophosphorus compounds.
MMRF March 07 Book.qxd  4/16/07  8:36 AM  Page 73
Oxtime eff icacy against organophosphates CM&R 2007 : 1 (March)74
very stable and is only slowly regenerated by spontaneous
hydrolysis of the phosphate ester. While the AChE remains
phosphylated, its enzyme activity is inhibited and therefore
ACh accumulates in the synaptic clefts of muscles and
nerves, leading to overstimulation of cholinergic receptors
that is essentially “poisoning by endogenous ACh.”
Additionally, OPCs may also interact (inhibit) with other
serine esterases,34,35 may have a direct action on muscarinic
and nicotinic receptors binding to (with high/low affinity) and
modulating the function of these receptors,36 and may induce
specific organ lesions.37 Propyl, isopropyl, butyl, and higher
alkyl phosphates and phosphonates are more likely than
methyl or ethyl analogs to act with secondary targets.35 The
concentrations of OPCs required to act directly on nicotinic
receptors are much higher than those on muscarinic receptors,
suggesting that muscarinic receptors are more important as
secondary targets in OPC action. Combination of possible
interactions will produce resultant toxic effect(s) for the
particular OPC. The spectrum of effects is further modulated
by various toxicokinetic factors.38
In phase I of biotransformation, metabolic transformation of
OPCs occurs through six major reactions, most of which are
activation pathways: (1) oxidative desulfurations (conversion
of thiophosphate to the more toxic oxon form, e.g., parathion,
malathion, fenitrothion, diazinon, dimethoate, azinphos-
methyl, fonofos), (2) oxidative N-dealkylation (e.g.,
dicrotophos, monocrotophos, dimethoate, phosphamidon),
(3) oxidative O-dealkylation (e.g., chlorfenvinphos), (4)
thioether oxidation (e.g., disulfoton, phorate, fenthion,
demethon-S-methyl), (5) side chain oxidation (e.g.,
fenitrothion, diazinon), and (6) various nonoxidative reactions
(e.g., trichlorfon, naled). In phase II of biotransformation,
which is by definition, the detoxification phase, OPCs
undergo conjugation with endogenous substrates, such as
glucuronides and sulfates. Organophosphates are detoxified
by the action of carboxylesterases (CarbE) (e.g., malathion,
fentoate, soman, sarin, tabun), phosphorylphosphatases (e.g.,
pyrimiphos methyl, diazinon, paraoxon, DFP, soman, sarin,
tabun) and glutathione redox system (e.g., methyl parathion,
methyl paraoxon, fenitrothion, diazinon, dichlorvos,
bromophos, chlorfenvinphos, mevinphos), but are activated
by the cytochrome P450 system, NADPH-cytochrome P450
reductase and flavin-containing monooxygenases.39
CarbE plays an important role in the detoxification of OPCs
via hydrolysis of ester bonds in OPCs (carboxyl ester side
chain), as well as binding OPCs at the active site of CarbE
that reduces the free concentration of the OPC potentially
available to inhibit AChE.40 Differences in CarbE levels
contribute to species differences in the toxicity of OPCs
among mammals.
The most common pathway for the metabolism of OPCs 
is via hydrolysis, which results in removal of the more 
labile leaving group. Products of such hydrolysis are 
excreted in urine and are biomarkers of exposure. 
These include dimethylphosphate, dimethylthiophosphate,
dimethyldithiophosphate, dimethylphosphorothioate, diethyl-
phosphate, diethylthiophosphate, diethyldithiophosphate and
diethylphosphorothioate. Because insecticidal OPCs differ
mostly in the structure of the leaving group, the rates of
hydrolysis will differ from compound to compound, despite
similarity in some of the resulting urinary metabolites.41 The
enzymes (phosphorylphosphatases) involved in hydrolysis of
OPCs, and therefore inactivation, are present in many tissues
and have high activities in liver, intestine and plasma.
Whether activation or detoxification will be a dominant reaction
largely depends on the chemical structure of the OPC and its
interaction with enzyme systems. Toxicity depends on the
relative prevalence and intensity of these competing metabolic
pathways. Chemicals that provoke induction of the enzymes
involved in activation of OPCs can make them more toxic, as
well as the chemicals that inhibit enzymes included in the
detoxification phase and vice versa.40,42-44 However, clinical
impact of interactions due to inhibition/induction of enzymes
involved in detoxification or activation is difficult to predict
because they often produce effects on several enzyme systems.
Critical Toxic Effects
Exposure to OPCs can induce four different clinical
syndromes: (1) acute cholinergic crisis as a result of AChE
inhibition, (2) intermediate syndrome whose underlying
mechanism(s) is still unclear, (3) organophosphate-induced
delayed neuropathy that has been explained by the inhibition
of neuropathy target esterase, and (4) chronic
organophosphate induced neuropsychiatric disorder due to
long-term low-level exposure.
Acute cholinergic crisis immediately follows exposure to
OPC and includes signs and symptoms resulting from
hyperstimulation of muscarinic receptors (e.g., bradycardia,
bronchoconstriction, bronchorrhoea, hypotension, increased
gastrointestinal motility, abdominal cramps, miosis,
hypersalivation), nicotinic receptors (e.g., hypertension,
tachycardia, fibrillation, fasciculation, necrosis of striated
muscles), and both central muscarinic and nicotinic receptors
(e.g., tremor, movement incoordination, seizures, central
depression of respiration, coma, death). If death ensues, it is
usually due to asphyxia, i.e., after cessation of respiration
followed by hypoxaemia and cyanosis. The so-called lung
muscarinic syndrome (laryngospasm, bronchoconstriction
and bronchorrhoea) and a depolarization paralysis of the
respiratory muscles also contribute to the occurrence of
asphyxia and death. Although the immediate cause of death
could also be cardiac arrest or heart failure, central
respiratory failure due to loss of respiratory drive is by far the
most frequent cause of death after intoxication with OPCs.5
Treatment of Organophosphate Poisoning
The current view of the treatment of OPC poisoning includes
three strategies: (1) the use of an anticholinergic drug (e.g.,
atropine), (2) cholinesterase-reactivating agents (e.g., oximes)
and (3) anticonvulsant drugs (e.g., benzodiazepines). The
development of treatment against OPC poisoning started with
recognition of the efficacy of atropine as an antidote for their
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parasympathomimetic effects. Atropine, an alkaloid isolated
from Atropa belladonna L. by Main in 1835, first
successfully used against a cholinesterase-inhibiting agent by
Fraser in 1863, has remained the cornerstone of the therapy of
OPC intoxication ever since. As far as chemical warfare
agents are concerned, Eberhard Gross, after a remark that
OPCs could exert their toxic action in a similar manner as
carbamates (including physostigmine), suggested the use of
atropine in the treatment of OPC poisoning.1 Experimental
work performed after World War II has revealed that atropine
affords much less efficient protection against OPCs than
against carbamate intoxications, making atropine
monotherapy insufficient in severe acute organophosphate
poisoning. This is mainly due to the fact that atropine, as an
antimuscarinic drug, is not capable of counteracting effects
provoked by nicotinic hyperstimulation, while at the same
time, possesses only limited antimuscarinic action in the
central nervous system (CNS). Also, convulsions can be
blocked by atropine only for a very limited time after
exposure to OPCs since other transmitter systems have
become involved in cholinergic overstimulation in the brain
(e.g., γ-aminobutyric acid, glutamate). Nevertheless, atropine is
the initial drug of choice in acute organophosphate poisoning.
The most important anticonvulsant in present use is
diazepam.45,46 The combination of atropine and diazepam is
more effective than atropine or oxime alone in reducing
mortality.47 Basically, the benzodiazepines potentiate the action
of the inhibitory neurotransmitter γ-aminobutyric acid at its
receptors.48-51 In the cholinergic nervous system, diazepam
probably decreases the synaptic release of ACh.52 The main
consequence of the action of benzodiazepines in CNS is
hyperpolarization of neurons which makes them significantly
less susceptible to cholinergically-induced depolarization. The
ultimate result is cessation of propagation of convulsions.53
Diazepam is of benefit in organophosphate poisoned patients
by reducing anxiety, restlessness and muscle fasciculations,
terminating convulsions, and reducing morbidity and mortality
when used in conjunction with atropine and oxime. Diazepam
should be given to patients poisoned with OPCs whenever
convulsions or pronounced muscle fasciculation are present. In
severe poisoning, diazepam administration should be
considered even before these complications develop.54
Oxime Therapy
The first successful (in vitro) destruction of phosphylated
AChE was accomplished by hydroxylamine in 1951.1
Additionally, in in vitro experiments, hydroxylamine also
induced reactivation of AChE inhibited by
tetraethylpyrophosphate.55 In the following years,
development of specific antidotes, originally aimed to
regenerate AChE inhibited by nerve agents, has been based on
the presumption that successful regeneration of inhibited
enzymes could be achieved by the nucleophilic attack of a
compound structurally similar to the chemical structure of
ACh, meaning a presence of a quaternary ammonia group in
a molecule of reactivators. Namely, pralidoxime (PAM-2), the
first pyridinium oxime, could reactivate the phosphylated
enzyme about a million times faster than hydroxylamine.56
By 1956, the scientific public was introduced to the use of the
newly synthesized oxime, PAM-2, which was administered
against parathion poisoning in Japan.57 Further investigations
in this area resulted in synthesis of bispyridinium oximes:
trimedoxime (TMB-4), obidoxime (LüH-6), HI-6, and HLö-7
(figure 3). These oximes were synthesized and introduced as
antidotes in 1957, 1964, 1967 and 1986, respectively.
PAM-2 (pyridinium-2-aldoxime) and TMB-4 Cl2 [1,3-Bis
(4-hydroxyiminomethyl-1-pyridinio) propane dichloride]
were synthesized in the United States.58,59 Chemically, 
LüH-6 Cl2 is 1,3-Bis(4-hydroxyiminomethyl-1-pyridinio)
-2-oxapropane dichloride. Oxime LüH-6 was named in 
honor of Lüttringhaus and Hagedorn who synthesized it in
Germany and introduced it into the medical practice.60
An oxime named HI-6 Cl2 [1-(2-hydroxyiminomethyl-
1-pyridinio)-3-(4-carbamoyl-1-pyridinio)-2-oxapropane
dichloride] was also synthesized by Hagedorn’s group in
Freiburg, Germany.61 The most recent Hagedorn oxime of
importance (after LüH-6 and HI-6) was HLö-7, named after
Hagedorn and Löffler.62 Chemically, this oxime is 
1-(((4-(aminocarbonyl)pyridinio)methoxy)methyl)-2,4-bis
((hydroxyimino)methyl) pyridinium diiodide. Thus far,
numerous attempts had been made to improve the antidotal
properties of the conventional mono- and bis-pyridinium
mono(di)-oximes by modifying their structure as well as by
the introduction of other heterocyclic systems, such 
Figure 3. Structural formulas for pyridinium oximes.
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as imidazolium, quinuclidinium, pyridinium-imidazolium,
pyridinium-quinuclidinium, and quinuclidinium-imidazolium
compounds.26,63-69 Additionally, recent experimental studies
conducted with 1,1’-methylene-bis(4-(hydroxyimino)methyl)
pyridinium dibromide (MMB-4) showed that, compared to
HLö-7 and HI-6, MMB-4 was a less potent reactivator of
AChE inhibited by sarin, several sarin analogues, soman, VX,
VR or CVX.3,70 Therefore, despite intensive research
activities on this topic, PAM-2, TMB-4, LüH-6, HI-6 and
HLö-7 have remained dominant among oximes in
experimental work.
Commercially available oximes are PAM-2 salts (e.g.,
chloride, mesylate, methylsulphate, iodide) and LüH-6
chloride. TMB-4 and HI-6 were in clinical use, however, now
these oximes are reserved for military use and are present in
auto-injectors of several armies.71-73 Although there are no
data on the clinical use of HLö-7, auto-injectors with this
oxime were also developed.70
Pyridinium oximes were formulated as different salts (e.g.,
chloride, iodide, bromide, lactate, methylsulphate,
methanesulfonate), which mostly differ in their stability and
solubility. Generally, PAM-2, TMB-4 and LüH-6 are stable in
aqueous solutions and can be prepared in liquid form in
ampules, whereas HI-6 and HLö-7 are not stable in aqueous
solutions and therefore can be kept for longer time only as
powder that is dissolved immediately before use.74,75
Consequently, HI-6 and HLö-7 are formulated as dry/wet
auto-injectors. Most papers on PAM-2 refer to the chloride or
methanesulfonate (mesylate, P2S) salts. These salts replaced
the first PAM-2 salt developed, PAM-2 iodide, because of its
limited solubility. It was also reported that PAM-2 iodide
might induce iodism.76 The anionic component of PAM-2,
however, does not significantly influence its antidotal
properties.77
Comparative studies on the two salts of HI-6 (i.e., chloride and
methanesulfonate) showed that HI-6 dimethanesulfonate (DMS)
is much more soluble and that its absolute water-solubility is two
and five times higher at 20°C and 5°C, respectively.78 Moreover,
comparative studies on reactivation potency, pharmacokinetics
and pharmacodynamics have demonstrated that the two HI-6
salts are equipotent in reactivating erythrocyte AChE inhibited
by highly toxic OPCs and that the two HI-6 salts have a similar
pharmacokinetic profile.79,80 In the frame of the Chemical
Biological Radiological Nuclear Research and Technology
Initiative, a project was launched aimed at developing 
auto-injectors based on HI-6 DMS.81 In the final stage of the
project, preclinical efficacy and toxicology data for jointly
administered HI-6 DMS, atropine and avizafone will be obtained
that will enable a phase 1 clinical trial to be conducted, thereby
determining the safety of the new nerve agent antidote system.
Mechanism of Action of Pyridinium Oximes
Reactivation of inhibited AChE by removal of the phosphyl
moiety from the AChE active site serine is considered to be
the primary mechanism of action for oximes. Clinical data
obtained in organophosphorus pesticide-poisoned patients
provide evidence for the validity of this assumption.82-84
As generally visualized, the oxime is oriented proximally to exert
a nucleophilic attack on the phosphorus of the enzyme-inhibitor
complex. Intermediate in the reactivation is a complex between
the phosphylated enzyme and the reactivator. The 
enzyme-inhibitor-oxime complex is then split off, leaving the
regenerated enzyme. However, phosphylated oximes formed
during the reactivation process might be potent inhibitors of
cholinesterases, which could cause re-inhibition of the
previously reactivated enzyme.85 Re-inhibition of AChE can be
faster than reactivation in the case when a phosphylated oxime
inhibits the enzyme at a rate higher than that of its elimination or
decay to non-toxic products.84,86
Early reports suggested this possibility on the basis of in vitro
experiments with LüH-6 and dimethoate,87 and LüH-6 and
PAM-2 with soman.88 Generally, phosphyloxime
accumulation may occur in the many reactivation/
re-inhibition cycles, particularly with the more stable
compounds deriving from 4-pyridinium oximes and may alter
the efficacy of the 4-pyridinium oximes.89-91 It remains
doubtful whether this occurs in humans with the usual dose
regimens. It was also demonstrated that human paraoxonase
with the prevailing Q192 phenotype92 is able to hydrolyze
effectively O,O-diethylphosphoryl LüH-6.93 This enzyme,
however, is apparently unable to inactivate phosphonyl oxime
derivatives.94
Mechanistic studies of oxime action have also shown that two
binding sites are involved, i.e., cholinesterases have two
binding sites for reversible ligands: (1) an acylation (catalytic)
site at the base of the active site gorge and (2) a peripheral
(allosteric) site at its mouth.95 Reversible ligands, such as the
oximes, may bind to cholinesterases either at the catalytic site
or at the allosteric site, or at both sites of the enzymes, thus
explaining the mechanism of protection afforded by oxime
administration.96 Bearing in mind the underlying mechanisms
of reactivation and protection, it becomes clear that
stereochemical arrangements of oximes can play a role in the
difference in their therapeutic efficacy. Finally, so-called
direct pharmacological effects such as direct reaction with
OPCs, anticholinergic and sympathomimetic effects, as well
as some pre-junctional properties that decrease the amount of
liberated acetylcholine into the synaptic cleft,97-101 are also
relevant for the interpretation of antidotal potency of oximes.
Regarding the aforementioned mechanism of protection, it is
possible to administer oximes before the poisoning occurs, i.e.,
prophylactically. Oximes, as reversible ligands, protect
cholinesterases from phosphylation by OPCs (i.e., oximes slow
down the rate of phosphylation).26 Oximes might be able to
reactivate the enzyme before a significant amount of aging has
time to occur. This approach has been tried by the British who
used P2S tablets as a pretreatment.102 However, short
elimination half-lives of the oximes make them inappropriate
for pre-treatment.83,103-105 Another prophylactic approach is a
combination of cholinesterase and an oxime pre-treatment that
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has been explored as a pseudo-catalytic bioscavenger, such that
the catalytic activity of inhibited cholinesterase can rapidly and
continuously be restored in the presence of an oxime.28
Clinical Use of Oximes
A particular problem in interpreting the beneficial role and
efficacy of oximes in clinical practice is a deficiency of
published data, especially those evaluated in controlled
clinical trials. In this section, in order to illustrate
heterogeneity of therapeutic approaches (i.e., dose regimen,
oxime choice and final outcome of the treatment) a few
studies are presented in chronological order of publication.
Sixty patients acutely poisoned with various
organophosphorus insecticides were treated with atropine,
diazepam and HI-6 (500 mg every 6 hours intramuscularly)
for 2 to 7 days, depending on the severity of the
organophosphate poisoning. In addition, in a small series of
patients (n=9), PAM-2 was administered instead in 1 g doses
every 6 hours over the same period of time. The recovery of
erythrocyte AChE was rapid in patients suffering from severe
phorate, quinalphos, dichlorvos and pyridafenthion
poisonings with reactivation half-lives ranging from 0.5 to 3.5
hours. Malathion-inhibited enzyme was reactivated much
more slowly (reactivation half-life=10.1 hours), while HI-6
was ineffective against AChE inhibition caused by dimethoate
and phosphoramidon. While nearly 100% reactivation of the
enzyme was obtained after only 2 days of HI-6 treatment,
PAM-2 could reactivate only 40% of the enzyme activity by
the end of the eighth day. No adverse effects were noted in
patients treated with oximes.82
Nine patients intoxicated with organophosphorus insecticides
were treated with PAM-2 methylsulphate (Contrathion) using
a dose of 4.42 mg/kg as a bolus injection followed by
continuous infusion 2.14 mg/kg/h.106 In patients with
ethylparathion and methylparathion poisonings, enzyme
reactivation could be obtained in some at oxime
concentrations as low as 2.88 mg/L. In others, however,
oxime concentration as high as 14.6 mg/L were ineffective.
The therapeutic effect of the oxime seemed to depend on the
plasma concentrations of ethylparathion and methylparathion.
Due to enzyme AChE re-inhibition, reactivation was absent as
long as these concentrations remained above 30 µg/L.
In a series of five case reports, LüH-6 (Toxogonin) 250 mg
was given as an intravenous bolus followed by continuous
infusion of 750 mg/24 hours in cases of life-threatening
parathion poisoning. This dose was effective, especially when
the dose of parathion absorbed was relatively low.83
In a clinical study of 63 patients poisoned with
organophosphorus insecticides, patients were divided into
three groups: one was treated with atropine only, while the
other two received atropine and either PAM-2 or LüH-6.
Loading and maintenance intravenous doses for PAM-2 were
30 mg/kg and 8 mg/kg/h, respectively and 8 mg/kg and 2
mg/kg/h, respectively, for LüH-6. There were no statistically
significant differences in the major clinical findings or AChE
activities on admission among the groups. Although the
severity of intoxications (based on respiratory complications
and duration of hospitalization) was higher in the atropine
plus oxime groups, no mortality was found in the PAM-2 plus
atropine group, whereas 12% and 50% of patients in the
atropine and atropine plus LüH-6 groups died, respectively.
Incidence of recurrent twitching and convulsions, repeated
respiratory arrest, required mechanical respiration, required
intensive care unit therapy and duration of hospitalization
were smaller in the atropine plus LüH-6 group than in the
atropine plus PAM-2 group. Three of the patients who
received the LüH-6 combination therapy developed hepatitis
and two of them died due to liver failure, which may indicate
overdosage of LüH-6.107
The usual therapeutic regimen of LüH-6 is comprised of a
250 mg intravenous (or intramuscular) bolus immediately
after the first atropine injection. Then if no recovery is
apparent during the next 15 to 30 minutes, an intravenous
infusion of 750 mg/24 h is started for as long as necessary.
Children can be treated with a 4 mg/kg bolus followed by an
infusion with 0.45 mg/kg/h. PAM-2 chloride can be used
according to the following scheme: 1 g intravenous bolus
followed by up to 0.5 g/h as an infusion. In children, a loading
dose of 25 to 50 mg/kg PAM-2 can be used, followed by
continuous infusion of 10 to 20 mg/kg/h.17 Other PAM-2 salts
are also on the market (i.e., iodide, methylsulfate and
mesylate) and can be used in corresponding doses.
Drawbacks and Limitations of Oxime Therapy
AChE inhibited by OPCs may undergo a secondary reaction,
i.e., spontaneous dealkylation through alkyl-oxygen bond
scission (aging), resulting in an irreversibly inactivated
enzyme. Velocity of aging has a great impact on the treatment
procedures and therapeutic efficacy of antidotes because aged
enzyme cannot be reactivated by oxime therapy. The aging
kinetics depend on the structure of the respective compound.
Thus, OPCs leading to dimethylphosphoryl-AChE (e.g.,
malaoxon) have a much shorter aging half-life (about 4 hours)
than compounds resulting in the diethylphosphoryl-enzyme
(e.g., paraoxon, diazinon).108
Oximes are not equally effective and rank order of
effectiveness changes with the OPC involved. Even if the
same dosage regimen of an oxime is administered, due to
interindividual variations, different plasma concentrations
will be obtained.109
Differences in their efficacy will be given not only throughout
interactions with organophosphorus insecticides but also via
their ability to counteract toxic effects of chemical nerve
agents (sarin, soman, tabun, and VX). This approach is due to
the permanent intention and effort of the scientific
community to develop an oxime with universal antidotal
properties, i.e., an oxime that is relatively efficient against all
OPCs, including chemical nerve agents.69,110-113
PAM-2 is very efficient in reactivating AChE inhibited with
sarin or VX,12,114-118 but is inefficient in the reactivation of
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the tabun-inhibited or soman-inhibited enzyme.119-121
Experiments have shown that TMB-4 is a powerful reactivator
and was the first oxime efficient in the treatment of animals
intoxicated with tabun65,122,123 and also effective against
experimental sarin or VX poisoning. However, TMB-4 is
totally ineffective against soman,65,119 and at the same time is
the most toxic oxime demonstrated in mice to have a median
lethal dose (LD50) of 3, 4 and 8 times less than the ones for
LüH-6, PAM-2 and HI-6, respectively.97 Oxime LüH-6,
recognized as a good AChE reactivator, shares similar
antidotal properties with TMB-4. Although potent against
tabun, sarin and VX,119,124 LüH-6 is also ineffective against
soman poisoning in mice,65 guinea pigs119 and primates.125
LüH-6 is somewhat more efficient than TMB-4 as an antidote
against tabun intoxication.126 Although being less toxic than
TMB-4, this oxime shows hepatotoxic potential.56,127
HI-6 is more potent than LüH-6 in protection of various
rodent species from intoxication with soman,117,119,128 as well
as sarin, and especially, VX.65 The only drawback of HI-6 is
that this oxime cannot reactivate tabun-inhibited AChE.129,130
The per se toxicity of HI-6 is low, actually the lowest among
the aforementioned oximes.65,97,131
HLö-7 reactivates AChE inhibited by any of the four major
nerve agents.132-134 In addition, HLö-7, more efficiently than
PAM-2, LüH-6 and HI-6, restored the neuromuscular
transmission impaired by in vitro superfusion of the 
neuro-muscular preparation with tabun, sarin, soman or
cyclosarin.135 It was found that HLö-7 induced a significant
reactivation of AChE in mice diaphragms previously inhibited
with tabun, sarin, soman and cyclosarin.136 Although both
HI-6 and HLö-7 can antagonize sarin-induced hypothermia
(thus proving that they can pass the blood-brain barrier and
gain access to the CNS when given with atropine),136,137 the
LD50 of HLö-7 is 2.5 times less than that of HI-6, indicating
the higher per se toxicity of the newer oxime.136 The
cardiovascular tolerability of HLö-7 was close, but still not as
good as HI-6, at least in anesthetized guinea pigs.138 On the
scale of efficacy, HLö-7 turned out to be somewhat more
effective than HI-6 against tabun and VX poisoning and less
effective against sarin and soman, as well as cyclosarin
intoxication.139,140 In guinea pigs, a species considered the
closest model to the primate, HLö-7-induced protection
against tabun poisoning was significantly better than that of
HI-6, while HI-6 was only slightly more efficient than HLö-7
in soman poisoning.141
In cases of intoxications with organophosphorus insecticides,
the worst therapeutic results are obtained with HI-6 and HLö-7
and, to some extent, PAM-2, while the most efficient oximes
are TMB-4 and LüH-6.83,142-144 Worek and co-workers86,143,145
have proved that equimolar concentrations of LüH-6 are more
effective than PAM-2, HI-6 and HLö-7 in in vitro reactivation
of human erythrocyte AChE inhibited by several
organophosphorus insecticides. Also, a 10 µmol/L
concentration of LüH-6, ten times less than PAM-2 (100
µmol/L), was necessary to restore the contractility of isolated
mouse diaphragm previously treated with paraoxon. Although
efficient in patients intoxicated by low parathion doses, LüH-6
failed to antagonize the effects of high parathion doses,
probably due to a high re-inhibition rate.83 However, in the
same clinical study, LüH-6 was completely ineffective against
oxydemethon-methyl intoxication. Unfortunately, there is no
published clinical evidence on the use of TMB-4 in patients
poisoned by organophosphorus insecticides; therefore, its
comparison is impossible.
A clinical study of HI-6 administered intramuscularly at
doses up to 500 mg was performed in 22 healthy volunteers
and revealed no adverse effects. In patients poisoned by
several organophosphorus insecticides, HI-6 ensured fast
reactivation of erythrocyte AChE in almost all cases, except
in the cases of dimethoate and phosphamidon.82,103
However, AChE inhibited by several organophosphorus
insecticides, including dimethoate, demethon, triamiphos,
ethoprophos, profenofos, fenamiphos and pyridafenthion,
resists any attempt at reactivation with any oxime, probably
due to variations in phosphoryl moiety and distribution of
electronic charge.56,86,142 Finally, a systematic review of two
randomized controlled clinical trials did not result in final
proof of the efficacy of PAM-2 in the treatment of poisonings
induced by organophosphorus insecticides in humans,146
probably due to the methodological gaps in the trials included,
as indicated in the original publication.
Conclusion
There are many factors that influence oxime efficacy. Among
them it seems most important to mention the inhibitory
potential of OPCs and its toxicokinetics, aging kinetics of
inhibited AChE, reactivating property of oximes, and its
pharmacokinetics. However, the assessment of oximes
effectiveness in patients severely poisoned with
organophosphates is hampered by sedation, artificial
ventilation and other therapeutic measures, as well as by
varying individual clinical courses due to differences in type
and amount of poison ingested or time elapsed before
treatment starts. Substantial species differences hamper the
extrapolation of experimental data to humans. Furthermore,
frequently high and unrealistic doses/concentrations of
oximes are chosen for the investigations, creating a serious
problem for interpretation of experimental data. Aimed at
overcoming these uncertainties, by combining different
parameters, a promising dynamic model has been developed
which may serve as a tool for defining effective oxime
concentrations, for optimizing oxime treatment and for
developing animal models.134,147 This model enables the
simulation of dynamic changes in AChE activity by including
enzyme kinetic (i.e., inhibition, reactivation, aging),
pharmacokinetic and toxicokinetic parameters. Validation of
the model using in vitro enzyme kinetic constants and distinct 
in vivo inhibitor and oxime concentrations demonstrated a
good agreement between patient and calculated AChE
activities for parathion poisoning treated with LüH-6.
Based on the results of the reactivation studies for
organophosphorus insecticide-inhibited human AChE, LüH-6
seems to be the logical first choice therapy. However, due to
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the paucity of published clinical data, further studies are
needed to establish the optimal therapeutic regimen. This
comprises a permanent search for an oxime with universal
antidotal characteristics, as well as carefully designed and
harmonized protocols for experimental and clinical studies,
thus enabling reliable data that can be implemented in
comprehensive (re)assessment procedures with a minimum of
uncertainties.
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